Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alliance Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: Alok Sinha who wrote (357)	5/14/1999 10:54:00 PM
From: Cacaito	Respond to of 548

Dupont and ImaRx patent lawsuit against MolByos and Malllindckrodt. Check on prnewswire May 4. Fight is about US patent 5,547,656 relating low density gas filled microspheres Dupont/ImaRX(perflutren = Definity TM), pending FDA approval. Sonus has EchoGen (dodecafluoropentane) pending FDA approval. Echovist and Levovist (galactose based)from Schering apparently are poor contrast agents. Albunex from Malindcrodt is apparently a poor agent. But they also have Optisom (perfluropropane). Sonovue from Braco a poor agent (sulfur hexafluorine gas). Iodapamide ethyl ester, company? NC100100 from Nycomed is also in the race. From: Diagnostic Imaging, March 1999 pages 56-61. www.dimag.com I used the printed version. It seems to be a tough field. Allp at least has other applications in phase III. Schering seems to be with ALLP because their own product is not so efficient.

To: Alok Sinha who wrote (357)	5/17/1999 5:32:00 PM
From: Joinvestor	Read Replies (1) \| Respond to of 548

Alok Sinha Thanks for the response. It was well thought out and articulate. The problem that I have is that it has gotten to the point where they have to raise equity in the 3-4 range. That concerns me because it says that they can not raise capital in another market and are thus forced to give away equity and what I feel is a deflated price. I would prefer to see another partner come on board to help in the funding. One issue of note however, if they are as close to the promised land as we hope, then the sale of equity in the 3-4 range is probably a lesser evil than if they gave away rights to a development partner. The only problem is that we have no way of telling where we will be in 12 months when the additional funding runs out. I think they are betting the farm that Imagent will be on the market and funding the completion of the other products. If it is not, I think we are done and a sale of the assets is likely. Either way, I am on board sink or swim. As I see it, at this point the down side is 3 and the upside is significantly more. JMHO JO